11 results on '"Siefried, Krista J."'
Search Results
2. Phenobarbital to manage severe gamma‐hydroxybutyrate withdrawal: A case series
- Author
-
Freeman, Georgia, primary, Siefried, Krista J., additional, Roberts, Darren M., additional, Rodgers, Craig, additional, Nic Ionmhain, Una, additional, Ramanathan, Jay, additional, Ezard, Nadine, additional, and Brett, Jonathan, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta‐analysis of randomised controlled trials
- Author
-
Acheson, Liam S., primary, Williams, Benjamin H., additional, Farrell, Michael, additional, McKetin, Rebecca, additional, Ezard, Nadine, additional, and Siefried, Krista J., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Barriers to help‐seeking among music festival attendees in New South Wales, Australia
- Author
-
Page, Robert, primary, Healey, Amy, additional, Siefried, Krista J., additional, Harrod, Mary Ellen, additional, Franklin, Erica, additional, Peacock, Amy, additional, Barratt, Monica J., additional, and Brett, Jonathan, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Correlates of higher‐risk drug‐related behaviours at music festivals in New South Wales, Australia
- Author
-
Healey, Amy, primary, Siefried, Krista J., additional, Harrod, Mary Ellen, additional, Franklin, Erica, additional, Peacock, Amy, additional, Barratt, Monica J., additional, and Brett, Jonathan, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Methamphetamine and emerging drugs of concern: A training needs analysis of Australian alcohol and other drug helplines.
- Author
-
Bascombe F, Siefried KJ, Clifford B, Child S, Loos R, Sgouras H, Stevens L, Wilson H, and Ezard N
- Subjects
- Humans, Middle Aged, Cross-Sectional Studies, Queensland, Victoria, Workforce, Methamphetamine, Health Services, Indigenous
- Abstract
Introduction: Fielding greater than 100,000 calls annually, telephone helplines are an important point of entry to alcohol and other drug (AOD) support and services in Australia. Methamphetamine and emerging drugs can present a particular challenge for this workforce. We sought to identify training needs for these services, so that appropriate targeted resources can be developed., Methods: We distributed an anonymous, online, cross-sectional survey to helpline staff from New South Wales, Queensland, South Australia, Victoria and Western Australia. Based on the WHO Hennessy-Hicks training needs analysis tool, participants were asked: to rate on a 7-point likert scale the importance of a topic to their practice and how well they perform in relation to the topic; open-ended questions specifying their own self-perceived training needs; and demographic data., Results: Of 50 participants, 29 completed the full survey (median age 49 [IQR 30-57.5]; median time working in AOD sector 6 years [IQR 1-20]). The results identified a need for: practical community-informed population relevant information for culturally and linguistically diverse populations and Aboriginal and Torres Strait Islander peoples for calls relating to methamphetamine and emerging drugs of concern; training and resources with a particular focus on families and friends of people who use methamphetamine and emerging drugs; and readily accessible up-to-date information on new and emerging drugs and treatment of related disorders., Discussion and Conclusions: This training needs analysis provides a structured approach to supporting the first-line AOD counsellors to provide up-to-date and accurate information to assist Australians seeking information, support and advice., (© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2023
- Full Text
- View/download PDF
7. Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019.
- Author
-
Black E, Mammen K, Deacon RM, Ezard N, Mills L, Dunlop AJ, Montebello M, Reid D, Childs S, Bruno R, Shakeshaft A, Siefried KJ, Farrell M, Holmes J, and Lintzeris N
- Subjects
- Humans, Australia epidemiology, New South Wales epidemiology, Quality of Life, Retrospective Studies, Ethanol, Sociological Factors, Amphetamine, Opioid-Related Disorders
- Abstract
Introduction: Amphetamine type substances (ATS) are commonly used by Australian alcohol and other drug service entrants. We describe demographic characteristics, patterns of ATS and other substance use, health and social conditions among clients entering New South Wales (NSW) public alcohol and other drug services., Methods: Retrospective cohort of 13,864 records across six health districts (2016-2019) for clients seeking substance use treatment. These districts service approximately 44% of the NSW population aged 15 years and over. Multivariate analysis was conducted on a subsample for whom full data were available (N = 9981). Data included NSW Minimum Data Set for drug and alcohol treatment services and Australian Treatment Outcomes Profile items., Results: Over the preceding 4 weeks, 77% (n = 10,610) of clients (N = 13,864) reported no recent ATS use, 15% (n = 2109) reported 'low frequency' (1-12 days) and 8% (n = 1145) 'high frequency' (13-28 days) use. ATS use was most common among people attending for ATS or opioids as primary drug of concern. A multinomial regression (N = 9981) identified that clients reporting recent arrest (aOR 1.74, 95% CI 1.36, 2.24), higher cannabis use frequency (aOR 1.01, 95% CI 1.00, 1.02), lower opioid use frequency (aOR 0.98, 95% CI 0.97, 0.99) and poorer quality of life (aOR 0.91, 95% CI 0.86, 0.97) were more likely to report 'high frequency' rather than 'low frequency' ATS use., Discussion and Conclusions: People who use ATS experience health and social issues that may require targeted responses. These should be integrated across all services, not only for clients with ATS as principal drug of concern., (© 2022 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2023
- Full Text
- View/download PDF
8. Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials.
- Author
-
Acheson LS, Williams BH, Farrell M, McKetin R, Ezard N, and Siefried KJ
- Subjects
- Male, Humans, Female, Randomized Controlled Trials as Topic, Substance Withdrawal Syndrome drug therapy, Methamphetamine adverse effects
- Abstract
Issues: Cessation of methamphetamine use may result in a characteristic withdrawal syndrome, no medication has been approved for this indication. This systematic review aims to assess the efficacy of pharmacotherapy for methamphetamine withdrawal, the first comprehensive meta-analysis since 2008., Approach: MEDLINE (1966-2020), CINAHL (1982-2020), PsychINFO (1806-2020) and EMBASE (1947-2020) were systematically searched. Studies were included if they were randomised controlled trials (RCT) investigating pharmacological treatments for methamphetamine withdrawal, reviewing outcomes of treatment discontinuation, mental health outcomes, withdrawal symptoms (including craving) and patient safety. The relative risk (RR) and weighted mean difference (MD) were used to meta-analyse dichotomous and continuous data respectively, with 95% confidence intervals. Risk of bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) assessments were conducted., Key Findings: Nine RCTs of six medications (n = 242 participants) met inclusion criteria, however, only six trials of four medications (n = 186) could be meta-analysed. Mean sample size across studies was 27 participants, and 88% of participants were male. The quality of evidence in this review varies from low to very low on GRADE assessments. Amineptine may reduce discontinuation rates (RR 0.22, 95% confidence interval [CI] 0.07, 0.72, p = 0.01), and improve global state (MD -0.49, 95% CI -0.80, -0.17), compared with placebo, however, this medication is no longer approved. No other medications improved any domain when compared with placebo. Due to lack of reporting safety profiles could not be established., Conclusions: There is insufficient evidence to indicate any medication is effective for the treatment of methamphetamine withdrawal. The poor quality of the evidence indicates a need for better powered, high-quality trials., (© 2022 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2023
- Full Text
- View/download PDF
9. Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series.
- Author
-
Freeman G, Siefried KJ, Roberts DM, Rodgers C, Nic Ionmhain U, Ramanathan J, Ezard N, and Brett J
- Subjects
- Humans, Prospective Studies, Phenobarbital therapeutic use, Benzodiazepines therapeutic use, Sodium Oxybate therapeutic use, Substance Withdrawal Syndrome drug therapy, Delirium chemically induced, Delirium drug therapy
- Abstract
Introduction: Management of a withdrawal syndrome following cessation of regular gamma-hydroxybutyrate (GHB) use, and its precursors, can represent a clinical challenge due to rapid onset delirium and/or seizures. Severe GHB withdrawal can be characterised by persistent or worsening features despite increasing benzodiazepine doses and regular baclofen. Barbiturates, such as phenobarbital, are an appealing option in this context due to their unique GABA-A receptor action., Case Series: This series describes the use of phenobarbital in 13 cases, 12 patients, across two hospitals in Sydney, Australia, with persistent or progressive GHB withdrawal despite benzodiazepine-based management. A median cumulative dose of oral diazepam prior to commencing phenobarbital was 120 mg (range 80-255 mg). The median time from the last GHB use to the first dose of phenobarbital was 24 h (range 7-57 h). Eight cases received phenobarbital orally on a general ward and 5 intravenously in intensive care units. An improvement in GHB withdrawal symptoms was observed after phenobarbital in all cases and there were no adverse events related to phenobarbital., Discussion and Conclusion: This case series suggests that phenobarbital for the management of benzodiazepine-resistant GHB withdrawal can be safe, even in general inpatient settings, and may avert the progression of delirium. Most data on the management of GHB withdrawal comes from case reports or series, such as this one. This highlights the need for prospective trials to establish an evidence base for therapeutic approaches, including validated measures of withdrawal severity and more information relating to the safe and effective dosing of phenobarbital., (© 2022 Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2023
- Full Text
- View/download PDF
10. Correlates of higher-risk drug-related behaviours at music festivals in New South Wales, Australia.
- Author
-
Healey A, Siefried KJ, Harrod ME, Franklin E, Peacock A, Barratt MJ, and Brett J
- Subjects
- Animals, Australia epidemiology, Dogs, Holidays, Humans, Male, New South Wales epidemiology, Illicit Drugs, Music, Substance-Related Disorders epidemiology
- Abstract
Introduction: There are few contemporary data on illicit drug use at music festivals. We describe drug use patterns and prevalence of specific higher-risk drug-related behaviours, and their associations with festivalgoer characteristics., Methods: We approached attendees at six major music festivals in New South Wales, Australia, from November 2019 to March 2020. Participants self-completed an anonymous survey on prior and intended drug use and associated higher-risk behaviours; double dropping; higher-volume ethanol alongside drug use; higher quantity 3,4-methylenedioxymethamphetamine (MDMA); mixing stimulants; and preloading. Logistic regression and UpSet analyses were performed to identify festivalgoer characteristics and the intersection of high-risk behaviours, respectively., Results: Of 1229 participants, 372 (30.3%) used or planned to use drugs at the festival. In multivariable analyses, men and those purchasing drugs both inside and outside the venue had greater odds of engaging in higher-risk behaviours. Of those using MDMA, 47.9% reported double dropping. People using drugs for the first time had 3.3 (95% confidence interval 1.2-8.7) greater odds of higher-volume ethanol alongside drug use. People reporting that police/police dog presence influenced their decision to take drugs had 2.2 (95% confidence interval 1.4-3.6) greater odds of preloading. In UpSet analysis, preloading was the most common intersection (17% of those using drugs)., Discussions and Conclusions: Engagement in the five higher-risk drug behaviours was common, particularly amongst males and those using drugs for the first time, while police/police dog presence appeared to influence higher-risk behaviours amongst festival attendees. This information can be used to inform harm reduction advice, public health and law enforcement strategies., (© 2021 Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2022
- Full Text
- View/download PDF
11. A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia.
- Author
-
Siefried KJ, Ezard N, Christmass M, Haber P, and Ali R
- Subjects
- Adult, Attitude, Communication, Humans, Research, Surveys and Questionnaires, Methamphetamine adverse effects
- Abstract
Introduction: This study aimed to gather a range of opinions, including those of affected people (consumers, concerned others) to identify clinical research priorities for methamphetamine and emerging drugs of concern in Australia, to guide the work of the National Centre for Clinical Research on Emerging Drugs (NCCRED)., Methods: A priority setting study was conducted (February-March 2019) in four phases: online stakeholder survey, thematic analysis of responses, rapid literature review, expert panel ranking of priorities against predetermined criteria., Results: Forty-seven respondents completed the survey, including people identifying as one or more of: researcher (53%, n = 25), clinician (45%; n = 21), family/friend/caregiver of someone who uses methamphetamine/emerging drugs (15%, n = 7) and consumer of methamphetamine/emerging drugs (13%, n = 6). Expert panel, evidence-informed top-ranked clinical research priorities for methamphetamine were: strategies to overcome barriers to intervention uptake, pilot medication trials for adults seeking treatment, and communication strategies regarding evidence-based treatments. For emerging drugs of concern, top-ranked priorities were: piloting community-located drug checking, feasibility of social media/other opportunities to alert consumers of emerging risks, GHB overdose and withdrawal management, and impacts of an early warning information system on reducing harms., Discussion and Conclusions: We demonstrate feasibility of a structured, collaborative clinical research priority setting process. Results have informed the establishment of NCCRED; using the identified priorities to guide seed funding, fellowships/scholarships and research programs. Broader uptake of this methodology by policymakers/research funders would assist to embed areas of concern identified by affected communities and other stakeholders in research prioritisation., (© 2021 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.